{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:03:22Z","timestamp":1790805802438,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007176","name":"Scuola Superiore Sant'Anna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007176","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Cardiac amyloidosis (CA) is a condition caused by interstitial infiltration of misfolded proteins structured into amyloid fibrils. Transthyretin (ATTR) and immunoglobulin light chain (AL) amyloidosis represent the most common forms of CA. CA was traditionally perceived as a rare and incurable disease, but diagnostic and therapeutic advances have undermined the conventional paradigm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The standard of care for ATTR-CA include agents capable of selectively stabilizing the precursor protein (e.g., tafamidis), whereas the plasma cell clone is the main target of chemotherapy for AL-CA. For long, tafamidis represented the only drug approved for patients with ATTR-CA. Recent data from ATTRibute-CM led to the approval of acoramidis, whereas patisiran received refusal based on the APOLLO-B trial. Novel CRISPR-Cas9-based drugs (i.e., NTLA-2001) hold great potential in the setting of ATTR-CA. Several hematological regimens are available to treat AL-CA. The main limit of current therapies is their inability to trigger removal of amyloid from tissues. However, the investigation of monoclonal antibodies targeting misfolded ATTR (e.g., PRX004, NI301A) or AL (e.g., birtamimab, anselamimab) has led to encouraging results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Various cutting-edge strategies are being tested for treatment of CA and may change the prognostic landscape of this condition in the next years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-025-00701-4","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:39:52Z","timestamp":1744695592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions"],"prefix":"10.1007","volume":"22","author":[{"given":"Yu Fu","family":"Ferrari Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Chubuchna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Morfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"10038","key":"701_CR1","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354.","journal-title":"Lancet"},{"issue":"3","key":"701_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.hfc.2024.02.002","volume":"20","author":"P Morfino","year":"2024","unstructured":"Morfino P, Aimo A, Franzini M, et al. Pathophysiology of cardiac amyloidosis. Heart Fail Clin. 2024;20(3):261\u201370.","journal-title":"Heart Fail Clin"},{"issue":"10","key":"701_CR3","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res. 2021;128(10):1554\u201375.","journal-title":"Circ Res"},{"issue":"17","key":"701_CR4","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/2047487319877708","volume":"27","author":"G Vergaro","year":"2020","unstructured":"Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. 2020;27(17):1806\u201315.","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"701_CR5","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","volume":"118","author":"A Porcari","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517\u201335.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"701_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","volume":"4","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar AD, Fontana M, Quarta CC, et al. AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2022;4(4):427\u201341.","journal-title":"JACC CardioOncol"},{"issue":"45","key":"701_CR7","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","volume":"40","author":"M Emdin","year":"2019","unstructured":"Emdin M, Aimo A, Rapezzi C, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J. 2019;40(45):3699\u2013706.","journal-title":"Eur Heart J"},{"key":"701_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.05.018","volume":"271","author":"A Aimo","year":"2018","unstructured":"Aimo A, Buda G, Fontana M, et al. Therapies for cardiac light chain amyloidosis: an update. Int J Cardiol. 2018;271:152\u201360.","journal-title":"Int J Cardiol"},{"issue":"Suppl B","key":"701_CR9","doi-asserted-by":"publisher","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","volume":"25","author":"M Emdin","year":"2023","unstructured":"Emdin M, Morfino P, Crosta L, et al. Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. Eur Heart J Suppl. 2023;25(Suppl B):B79\u201384.","journal-title":"Eur Heart J Suppl"},{"key":"701_CR10","doi-asserted-by":"crossref","unstructured":"Morfino P, Aimo A, Vergaro G et al. Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy. Pharmaceutics. 2023;15(4).","DOI":"10.3390\/pharmaceutics15041129"},{"issue":"24","key":"701_CR11","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"701_CR12","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","volume":"6","author":"G Merlini","year":"2013","unstructured":"Merlini G, Plante-Bordeneuve V, Judge DP, et al. Effects of Tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011\u201320.","journal-title":"J Cardiovasc Transl Res"},{"issue":"11","key":"701_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"8","key":"701_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin Familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","journal-title":"Neurology"},{"issue":"12","key":"701_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ene.12225","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron P, Theaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin Familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539\u201345.","journal-title":"Eur J Neurol"},{"issue":"1","key":"701_CR16","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS, et al. Long-Term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193.","journal-title":"Circ Heart Fail"},{"key":"701_CR17","doi-asserted-by":"crossref","unstructured":"Rapezzi C, Kristen AV, Gundapaneni B et al. Benefits of Tafamidis in patients with advanced transthyretin amyloid cardiomyopathy. Eur Heart J. 2020;41(Supplement_2).","DOI":"10.1093\/ehjci\/ehaa946.2115"},{"issue":"1","key":"701_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P, et al. Effect of Tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: A post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 2024;9(1):25\u201334.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"701_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","volume":"12","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Sultan MB, Gundapaneni B, et al. Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing Long-Term extension study. JACC Heart Fail. 2024;12(1):150\u201360.","journal-title":"JACC Heart Fail"},{"issue":"15","key":"701_CR20","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ, et al. Cost-Effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141(15):1214\u201324.","journal-title":"Circulation"},{"issue":"24","key":"701_CR21","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the Familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013;110(24):9992\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"701_CR22","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1177\/10600280211000351","volume":"55","author":"JD Yadav","year":"2021","unstructured":"Yadav JD, Othee H, Chan KA, et al. Transthyretin amyloid Cardiomyopathy-Current and future therapies. Ann Pharmacother. 2021;55(12):1502\u201314.","journal-title":"Ann Pharmacother"},{"issue":"Suppl1","key":"701_CR23","first-page":"A14214","volume":"140","author":"JD Gillmore","year":"2019","unstructured":"Gillmore JD, Garcia-Pavia P, Grogan M, et al. Abstract 14214: ATTRibute-CM: A randomized, Double-Blind, Placebo-Controlled, Multi-Center, global phase 3 study of AG10 in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Circulation. 2019;140(Suppl1):A14214\u201314214.","journal-title":"Circulation"},{"key":"701_CR24","unstructured":"BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study. 2021 [cited 12.27.2021]. Available from: https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-month-12-topline-results-from-phase-3-attribute-cm-study\/"},{"key":"701_CR25","unstructured":"Trial demonstrates potential. of acoramidis for transthyretin amyloid cardiomyopathy. ATTRibute-CM trial presented in a Hot Line session today at ESC Congress 2023."},{"issue":"2","key":"701_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"key":"701_CR27","unstructured":"BridgeBio P. Bridgebio Pharma announces U.S. Food and Drug Administration (FDA) acceptance of New Drug Application (NDA) for ACORAMIDIS for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-cm). BridgeBio Pharma. February 5, 2024. Accessed February 5, 2024. Available from: https:\/\/investor.bridgebio.com\/news-releases\/news-release-details\/bridgebio-pharma-announces-us-food-and-drug-administration-fda"},{"key":"701_CR28","unstructured":"Bridgebio pharma and bayer announce european licensing agreement for acoramidis in ATTR-CM. 2024 [03.04.2024]. Available from: https:\/\/investor.bridgebio.com\/news-releases\/news-release-details\/bridgebio-pharma-and-bayer-announce-european-licensing-agreement\/"},{"issue":"4","key":"701_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13506120600960882","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236\u201349.","journal-title":"Amyloid"},{"issue":"24","key":"701_CR30","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for Familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658\u201367.","journal-title":"JAMA"},{"issue":"9","key":"701_CR31","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G, Pipilas A, Mussinelli R, et al. Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2020;26(9):753\u20139.","journal-title":"J Card Fail"},{"key":"701_CR32","first-page":"1","volume":"9","author":"J Koyama","year":"2015","unstructured":"Koyama J, Minamisawa M, Sekijima Y, et al. Left ventricular deformation and torsion assessed by speckle-tracking echocardiography in patients with mutated transthyretin-associated cardiac amyloidosis and the effect of diflunisal on myocardial function. Int J Cardiol Heart Vasc. 2015;9:1\u201310.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"2","key":"701_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","volume":"27","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim M, Saint Croix GR, Lacy S, et al. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev. 2022;27(2):517\u201324.","journal-title":"Heart Fail Rev"},{"issue":"10","key":"701_CR34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"A Aimo","year":"2022","unstructured":"Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022;19(10):655\u201367.","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"701_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553\u201365.","journal-title":"N Engl J Med"},{"issue":"6","key":"701_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"701_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","volume":"9","author":"I Urits","year":"2020","unstructured":"Urits I, Swanson D, Swett MC, et al. A review of Patisiran (ONPATTRO(R)) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9(2):301\u201315.","journal-title":"Neurol Ther"},{"issue":"2","key":"701_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","volume":"37","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023;37(2):127\u201342.","journal-title":"BioDrugs"},{"issue":"1","key":"701_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"701_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, et al. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary Transthyretin-Mediated amyloidosis. Circulation. 2019;139(4):431\u201343.","journal-title":"Circulation"},{"issue":"1","key":"701_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with Patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189\u201399.","journal-title":"JACC Cardiovasc Imaging"},{"key":"701_CR42","unstructured":"Alnylam announces receipt of Complete Response Letter from US FDA for supplemental New Drug Application for patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis. News release. October 9. 2023. Available from: https:\/\/www.businesswire.com\/news\/home\/20231009982660\/en\/Alnylam-Announces-Receipt-of-Complete-Response-Letter-from-U.S.-FDA-for-Supplemental-New-Drug-Application-for-Patisiran-for-the-Treatment-of-the-Cardiomyopathy-of-ATTR-Amyloidosis"},{"issue":"Supplement2","key":"701_CR43","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/eurheartjsupp\/suae036.002","volume":"26","author":"S Longhi","year":"2024","unstructured":"Longhi S, Mauer M, Berk J, APOLLO\u2013B, OPEN\u2013LABEL EXTENSION STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS, et al. Eur Heart J Supplements. 2024;26(Supplement2):ii1\u20131.","journal-title":"Eur Heart J Supplements"},{"issue":"Suppl1","key":"701_CR44","first-page":"A13273","volume":"148","author":"RR Hung","year":"2023","unstructured":"Hung RR, Correia Ed, Berk JL, et al. Abstract 13273: APOLLO-B, a study of Patisiran in patients with transthyretin cardiac amyloidosis: primary Long-Term results from the Open-Label extension period. Circulation. 2023;148(Suppl1):A13273\u201313273.","journal-title":"Circulation"},{"issue":"2","key":"701_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"BA Habtemariam","year":"2021","unstructured":"Habtemariam BA, Karsten V, Attarwala H, et al. Single-Dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, Vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"701_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139.","journal-title":"Amyloid"},{"issue":"17 Supplement 2","key":"701_CR47","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1212\/WNL.0000000000202920","volume":"100","author":"M Polydefkis","year":"2023","unstructured":"Polydefkis M, Birklein F, Sekijima Y, et al. Comparison of efficacy outcomes with Vutrisiran vs. Patisiran in hATTR amyloidosis with polyneuropathy: Post-hoc analysis of the HELIOS-A study (S14.003). Neurology. 2023;100(17 Supplement 2):2963.","journal-title":"Neurology"},{"issue":"2","key":"701_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","volume":"26","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Grogan M, Kale P, et al. Impact of Vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024;26(2):397\u2013410.","journal-title":"Eur J Heart Fail"},{"issue":"11Supplement1","key":"701_CR49","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1016\/S0735-1097(20)34206-6","volume":"75","author":"R Shilling","year":"2020","unstructured":"Shilling R, Karsten V, Silliman N, STUDY DESIGN AND RATIONALE OF HELIOS-B:, A PHASE 3 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY. J Am Coll Cardiol. 2020;75(11Supplement1):3579\u20133579.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"701_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"701_CR51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12883-023-03116-7","volume":"23","author":"A Yarlas","year":"2023","unstructured":"Yarlas A, Lovley A, Brown D, et al. The impact of Inotersen on neuropathy impairment score in patients with hereditary transthyretin amyloidosis with polyneuropathy. BMC Neurol. 2023;23(1):108.","journal-title":"BMC Neurol"},{"issue":"6","key":"701_CR52","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","volume":"59","author":"TP Prakash","year":"2016","unstructured":"Prakash TP, Yu J, Migawa MT, et al. Comprehensive Structure-Activity relationship of triantennary N-Acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J Med Chem. 2016;59(6):2718\u201333.","journal-title":"J Med Chem"},{"key":"701_CR53","unstructured":"WAINUA\u2122 (eplontersen). granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis. Available from: https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/wainuatm-eplontersen-granted-regulatory-approval-us-treatment"},{"issue":"1","key":"701_CR54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney NJ, Guo S, Tai LJ, et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 2021;8(1):652\u201361.","journal-title":"ESC Heart Fail"},{"issue":"15","key":"701_CR55","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W Jr., Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358.","journal-title":"JAMA"},{"key":"701_CR56","unstructured":"Eplontersen met co-primary. And secondary endpoints in interim analysis of the NEURO-TTRansform phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)."},{"issue":"2","key":"701_CR57","doi-asserted-by":"publisher","first-page":"e030512","DOI":"10.1161\/JAHA.123.030512","volume":"13","author":"AL Yu","year":"2024","unstructured":"Yu AL, Chen YC, Tsai CH, et al. Use of Technetium-99m-Pyrophosphate Single-Photon emission computed tomography\/computed tomography in monitoring therapeutic changes of Eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2024;13(2):e030512.","journal-title":"J Am Heart Assoc"},{"key":"701_CR58","unstructured":"Ionis completes enrollment in. landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy."},{"issue":"39","key":"701_CR59","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.2174\/0113816128267417231127070901","volume":"29","author":"G Panichella","year":"2023","unstructured":"Panichella G, Aimo A. CRISPR-Cas9 for the treatment of transthyretin cardiac amyloidosis. Curr Pharm Des. 2023;29(39):3166\u20139.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"701_CR60","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, Smith AR, Patel MC, et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 2018;22(9):2227\u201335.","journal-title":"Cell Rep"},{"key":"701_CR61","unstructured":"Study to Evaluate Safety. Tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)."},{"issue":"18","key":"701_CR62","first-page":"1722","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Maitland ML, Lebwohl D. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. Reply. N Engl J Med. 2021;385(18):1722\u20133.","journal-title":"N Engl J Med"},{"key":"701_CR63","unstructured":"Julian D, Gillmore JT, Gane E, Bj\u00f6rn Pilebro ML, Maitland M, Stroh Y, Xu A, Boyd J, Cehelsky DE, Gutstein T, Ho A, Sonderfan L, Walsh D, Lebwohl, Fontana M. First-in-Human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 in patients with transthyretin (ATTR)Amyloidosis with cardiomyopathy. 05 November 20222022."},{"key":"701_CR64","unstructured":"MAGNITUDE. A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM). Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06128629"},{"key":"701_CR65","unstructured":"Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA. -2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy 2024 [cited March 18, 2024]. Available from: https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-announces-first-patient-dosed-phase-3"},{"issue":"6","key":"701_CR66","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","volume":"27","author":"P Morfino","year":"2022","unstructured":"Morfino P, Aimo A, Panichella G, et al. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Fail Rev. 2022;27(6):2187\u2013200.","journal-title":"Heart Fail Rev"},{"issue":"29","key":"701_CR67","doi-asserted-by":"publisher","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","volume":"115","author":"L Saelices","year":"2018","unstructured":"Saelices L, Chung K, Lee JH, et al. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its Inhibition. Proc Natl Acad Sci U S A. 2018;115(29):E6741\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"701_CR68","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1074\/jbc.RA118.005257","volume":"294","author":"L Saelices","year":"2019","unstructured":"Saelices L, Nguyen BA, Chung K, et al. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. J Biol Chem. 2019;294(15):6130\u201341.","journal-title":"J Biol Chem"},{"issue":"5","key":"701_CR69","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","volume":"36","author":"M Nuvolone","year":"2022","unstructured":"Nuvolone M, Nevone A, Merlini G. Targeting amyloid fibrils by passive immunotherapy in systemic amyloidosis. BioDrugs. 2022;36(5):591\u2013608.","journal-title":"BioDrugs"},{"issue":"23","key":"701_CR70","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMc2304584","volume":"388","author":"M Fontana","year":"2023","unstructured":"Fontana M, Gilbertson J, Verona G, et al. Antibody-Associated reversal of ATTR Amyloidosis-Related cardiomyopathy. N Engl J Med. 2023;388(23):2199\u2013201.","journal-title":"N Engl J Med"},{"issue":"48","key":"701_CR71","doi-asserted-by":"publisher","first-page":"25096","DOI":"10.1074\/jbc.M116.738138","volume":"291","author":"A Hosoi","year":"2016","unstructured":"Hosoi A, Su Y, Torikai M, et al. Novel antibody for the treatment of transthyretin amyloidosis. J Biol Chem. 2016;291(48):25096\u2013105.","journal-title":"J Biol Chem"},{"key":"701_CR72","unstructured":"Study A. of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis."},{"key":"701_CR73","unstructured":"Prothena Biosciences Limited. PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis. 2020."},{"key":"701_CR74","doi-asserted-by":"crossref","unstructured":"Suhr OGM, Martins de Silva A et al. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 Emerging Science Abstracts. 2021 AAN Annual meeting abstracts. Neurology. 2021;96(22):2783\u20138.","DOI":"10.1212\/WNL.0000000000012044"},{"key":"701_CR75","doi-asserted-by":"crossref","unstructured":"Fontana M, Buchholtz K, Engelmann MDM et al. NNC6019\u20130001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial. Eur Heart J. 2022;43(Supplement_2).","DOI":"10.1093\/eurheartj\/ehac544.1767"},{"issue":"1","key":"701_CR76","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon A, Hagenbuch A, Huy C, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12(1):3142.","journal-title":"Nat Commun"},{"issue":"3","key":"701_CR77","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med. 2023;389(3):239\u201350.","journal-title":"N Engl J Med"},{"key":"701_CR78","unstructured":"Initial safety of targeted immune activation with the amyloid depleter ALXN2220. 2024. Available from: https:\/\/esc365.escardio.org\/presentation\/280599"},{"issue":"4","key":"701_CR79","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","volume":"3","author":"G Bianchi","year":"2021","unstructured":"Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2021;3(4):467\u201387.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"701_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","volume":"29","author":"V Sanchorawala","year":"2022","unstructured":"Sanchorawala V, Boccadoro M, Gertz M, et al. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid. 2022;29(1):1\u20137.","journal-title":"Amyloid"},{"issue":"1","key":"701_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","volume":"30","author":"AD Wechalekar","year":"2023","unstructured":"Wechalekar AD, Cibeira MT, Gibbs SD, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023;30(1):3\u201317.","journal-title":"Amyloid"},{"issue":"1","key":"701_CR82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based treatment for Immunoglobulin Light-Chain amyloidosis. N Engl J Med. 2021;385(1):46\u201358.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"701_CR83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2021-146820","volume":"138","author":"R Comenzo","year":"2021","unstructured":"Comenzo R, Palladini G, Kastritis E, et al. Subcutaneous daratumumab with bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed light chain (AL) amyloidosis: 18-Month analysis of the phase 3 ANDROMEDA study. Blood. 2021;138(Supplement 1):159\u2013159.","journal-title":"Blood"},{"key":"701_CR84","doi-asserted-by":"crossref","unstructured":"Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol. 2005;79(4):319\u2013\u200928.","DOI":"10.1002\/ajh.20381"},{"issue":"2","key":"701_CR85","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bjh.16436","volume":"189","author":"T Popkova","year":"2020","unstructured":"Popkova T, Hajek R, Jelinek T. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020;189(2):228\u201338.","journal-title":"Br J Haematol"},{"issue":"1","key":"701_CR86","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.clml.2018.08.021","volume":"19","author":"SM Iqbal","year":"2019","unstructured":"Iqbal SM, Stecklein K, Sarow J, et al. Elotuzumab in combination with Lenalidomide and dexamethasone for Treatment-resistant Immunoglobulin light chain amyloidosis with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(1):e33\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"701_CR87","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","volume":"7","author":"CD Barrett","year":"2019","unstructured":"Barrett CD, Dobos K, Liedtke M, et al. A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail. 2019;7(11):958\u201366.","journal-title":"JACC Heart Fail"},{"key":"701_CR88","doi-asserted-by":"publisher","first-page":"1212983","DOI":"10.3389\/fcvm.2023.1212983","volume":"10","author":"P Morfino","year":"2023","unstructured":"Morfino P, Aimo A, Castiglione V, et al. Cardiovascular toxicity from therapies for light chain amyloidosis. Front Cardiovasc Med. 2023;10:1212983.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"701_CR89","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","volume":"13","author":"G Palladini","year":"2023","unstructured":"Palladini G, Schonland S, Merlini G, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19.","journal-title":"Blood Cancer J"},{"issue":"4","key":"701_CR90","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/hon.3135","volume":"41","author":"F Theodorakakou","year":"2023","unstructured":"Theodorakakou F, Briasoulis A, Fotiou D, et al. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease. Hematol Oncol. 2023;41(4):725\u201332.","journal-title":"Hematol Oncol"},{"issue":"18","key":"701_CR91","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood.2022016348","volume":"140","author":"M Basset","year":"2022","unstructured":"Basset M, Milani P, Foli A, et al. Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. Blood. 2022;140(18):1964\u201371.","journal-title":"Blood"},{"issue":"11","key":"701_CR92","doi-asserted-by":"publisher","first-page":"9627","DOI":"10.3390\/curroncol30110697","volume":"30","author":"S Das","year":"2023","unstructured":"Das S, Ailawadhi S, Sher T, et al. Anti-B cell maturation antigen chimeric antigen receptor T cell therapy for the treatment of AL amyloidosis and concurrent relapsed\/refractory multiple myeloma: preliminary efficacy and safety. Curr Oncol. 2023;30(11):9627\u201333.","journal-title":"Curr Oncol"},{"issue":"Supplement 1","key":"701_CR93","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2023-186450","volume":"142","author":"E Lebel","year":"2023","unstructured":"Lebel E, Kfir-Erenfeld S, Asherie N, et al. Feasibility of a novel academic Anti-BCMA chimeric antigen receptor T-Cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Blood. 2023;142(Supplement 1):538\u2013538.","journal-title":"Blood"},{"issue":"14","key":"701_CR94","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood.2022019406","volume":"142","author":"MA Gertz","year":"2023","unstructured":"Gertz MA, Cohen AD, Comenzo RL, et al. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023;142(14):1208\u201318.","journal-title":"Blood"},{"issue":"3","key":"701_CR95","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","volume":"23","author":"M Renz","year":"2016","unstructured":"Renz M, Torres R, Dolan PJ, et al. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (dagger). Amyloid. 2016;23(3):168\u201377.","journal-title":"Amyloid"},{"issue":"Supplement1","key":"701_CR96","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1182\/blood-2019-124482","volume":"134","author":"MA Gertz","year":"2019","unstructured":"Gertz MA, Cohen AD, Comenzo RL, et al. Results of the phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients. Blood. 2019;134(Supplement1):3166\u20133166.","journal-title":"Blood"},{"issue":"1","key":"701_CR97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","volume":"22","author":"A Wechalekar","year":"2022","unstructured":"Wechalekar A, Antoni G, Al Azzam W, et al. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovasc Disord. 2022;22(1):49.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"701_CR98","first-page":"284","volume":"38","author":"MB Pepys","year":"1979","unstructured":"Pepys MB, Dyck RF, de Beer FC, et al. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979;38(2):284\u201393.","journal-title":"Clin Exp Immunol"},{"issue":"34","key":"701_CR99","doi-asserted-by":"publisher","first-page":"E586","DOI":"10.1073\/pnas.1103247108","volume":"108","author":"JS Wall","year":"2011","unstructured":"Wall JS, Richey T, Stuckey A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci U S A. 2011;108(34):E586\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"701_CR100","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11307-011-0524-0","volume":"14","author":"JS Wall","year":"2012","unstructured":"Wall JS, Richey T, Williams A, et al. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol Imaging Biol. 2012;14(4):402\u20137.","journal-title":"Mol Imaging Biol"},{"key":"701_CR101","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3389\/fimmu.2017.01082","volume":"8","author":"JS Foster","year":"2017","unstructured":"Foster JS, Williams AD, Macy S, et al. A Peptide-Fc Opsonin with Pan-Amyloid reactivity. Front Immunol. 2017;8:1082.","journal-title":"Front Immunol"},{"key":"701_CR102","unstructured":"PAN-AMYLOID, REMOVAL & REVERSAL OF THE UNDERLYING PATHOLOGY OF SYSTEMIC AMYLOIDOSIS. Available from: https:\/\/attralus.com\/pipeline"},{"issue":"Supplement 1","key":"701_CR103","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2021-151908","volume":"138","author":"C Sirac","year":"2021","unstructured":"Sirac C, Jaccard A, Codo R, et al. Pre-Clinical characterization of a novel fusion protein (AT-03), with Pan-Amyloid binding and removal. Blood. 2021;138(Supplement 1):1207\u20131207.","journal-title":"Blood"},{"key":"701_CR104","unstructured":"Foster JS, Klein SGML, Bell G, Selvarajah S, Williams AD, Balachandran M, Jackson JW, Stuckey A, Martin E, Macy S, Wooliver DC, Heidel RE, Kennel SJ. J. S. Wall. Preclinical characterization of AT-04, a Pan\u2013Amyloid-Binding Fc Domain-Peptide fusion, to serve as an Opsonin for Macrophage-Mediated clearance of amyloid deposits. 2022."},{"key":"701_CR105","unstructured":"New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders. 2023. Available from: https:\/\/attralus.com\/press-releases\/attralus-presents-new-preclinical-data-on-at-04-and-at-07-pan-amyloid-removal-therapeutics-targeting-neurodegenerative-disorders-at-ad-pd-2023"},{"issue":"11","key":"701_CR106","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","volume":"16","author":"JS Wall","year":"2023","unstructured":"Wall JS, Martin EB, Lands R, et al. Cardiac amyloid detection by PET\/CT imaging of iodine ((124)I) Evuzamitide ((124)I-p5\u2009+\u200914): A phase 1\/2 study. JACC Cardiovasc Imaging. 2023;16(11):1433\u201348.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"701_CR107","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","volume":"34","author":"DP Judge","year":"2020","unstructured":"Judge DP, Kristen AV, Grogan M, et al. Phase 3 multicenter study of revusiran in patients with hereditary Transthyretin-Mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020;34(3):357\u201370.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-025-00701-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00701-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:02:50Z","timestamp":1768550570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-025-00701-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1007\/s11897-025-00701-4","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"21 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16"}}